Spider venom components decrease glioblastoma cell migration and invasion through RhoA-ROCK and Na
Cancer therapy
Cell adhesion
Cell morphology
Cytoskeleton
Metastasis
Phoneutria nigriventer
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
17 Dec 2020
17 Dec 2020
Historique:
received:
18
02
2020
accepted:
09
11
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Glioblastoma (GB) cells have the ability to migrate and infiltrate the normal parenchyma, leading to the formation of recurrent tumors often adjacent to the surgical extraction site. We recently showed that Phoneutria nigriventer spider venom (PnV) has anticancer effects mainly on the migration of human GB cell lines (NG97 and U-251). The present work aimed to investigate the effects of isolated components from the venom on migration, invasiveness, morphology and adhesion of GB cells, also evaluating RhoA-ROCK signaling and Na Human (NG97) GB cells were treated with twelve subfractions (SFs-obtained by HPLC from PnV). Migration and invasion were evaluated by scratch wound healing and transwell assays, respectively. Cell morphology and actin cytoskeleton were shown by GFAP and phalloidin labeling. The assay with fibronectin coated well plate was made to evaluate cell adhesion. Western blotting demonstrated ROCK and AMOG levels and a ROCK inhibitor was used to verify the involvement of this pathway. Values were analyzed by the GraphPad Prism software package and the level of significance was determinate using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test. Two (SF1 and SF11) of twelve SFs, decreased migration and invasion compared to untreated control cells. Both SFs also altered actin cytoskeleton, changed cell morphology and reduced adhesion. SF1 and SF11 increased ROCK expression and the inhibition of this protein abolished the effects of both subfractions on migration, morphology and adhesion (but not on invasion). SF11 also increased Na All components of the venom were evaluated and two SFs were able to impair human glioblastoma cells. The RhoA effector, ROCK, was shown to be involved in the mechanisms of both PnV components. It is possible that AMOG mediates the effect of SF11 on the invasion. Further investigations to isolate and biochemically characterize the molecules are underway.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma (GB) cells have the ability to migrate and infiltrate the normal parenchyma, leading to the formation of recurrent tumors often adjacent to the surgical extraction site. We recently showed that Phoneutria nigriventer spider venom (PnV) has anticancer effects mainly on the migration of human GB cell lines (NG97 and U-251). The present work aimed to investigate the effects of isolated components from the venom on migration, invasiveness, morphology and adhesion of GB cells, also evaluating RhoA-ROCK signaling and Na
METHODS
METHODS
Human (NG97) GB cells were treated with twelve subfractions (SFs-obtained by HPLC from PnV). Migration and invasion were evaluated by scratch wound healing and transwell assays, respectively. Cell morphology and actin cytoskeleton were shown by GFAP and phalloidin labeling. The assay with fibronectin coated well plate was made to evaluate cell adhesion. Western blotting demonstrated ROCK and AMOG levels and a ROCK inhibitor was used to verify the involvement of this pathway. Values were analyzed by the GraphPad Prism software package and the level of significance was determinate using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test.
RESULTS
RESULTS
Two (SF1 and SF11) of twelve SFs, decreased migration and invasion compared to untreated control cells. Both SFs also altered actin cytoskeleton, changed cell morphology and reduced adhesion. SF1 and SF11 increased ROCK expression and the inhibition of this protein abolished the effects of both subfractions on migration, morphology and adhesion (but not on invasion). SF11 also increased Na
CONCLUSION
CONCLUSIONS
All components of the venom were evaluated and two SFs were able to impair human glioblastoma cells. The RhoA effector, ROCK, was shown to be involved in the mechanisms of both PnV components. It is possible that AMOG mediates the effect of SF11 on the invasion. Further investigations to isolate and biochemically characterize the molecules are underway.
Identifiants
pubmed: 33327966
doi: 10.1186/s12935-020-01643-8
pii: 10.1186/s12935-020-01643-8
pmc: PMC7745393
doi:
Types de publication
Journal Article
Langues
eng
Pagination
576Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : 2015/04194-0
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 431465/2016-9
Références
Nature. 2009 Feb 12;457(7231):901-5
pubmed: 19118385
J Cell Biol. 1996 Jun;133(6):1403-15
pubmed: 8682874
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452
pubmed: 28031556
Neuro Oncol. 2013 Nov;15(11):1518-31
pubmed: 23887941
Cancer Res. 2006 Dec 15;66(24):11709-17
pubmed: 17178866
Curr Oncol Rep. 2017 Apr;19(4):23
pubmed: 28303490
Neurochem Res. 2017 Jun;42(6):1847-1863
pubmed: 28478595
Biochem J. 2002 Jan 15;361(Pt 2):243-54
pubmed: 11772396
Drug Discov Today. 2016 Feb;21(2):204-7
pubmed: 25617672
Hypertens Res. 2009 Oct;32(10):846-52
pubmed: 19662022
Cell Mol Neurobiol. 2002 Dec;22(5-6):579-88
pubmed: 12585681
J Neurol Sci. 2017 Dec 15;383:56-60
pubmed: 29246624
Toxicon. 2017 Apr;129:58-67
pubmed: 28202361
Cell Mol Neurobiol. 2005 Aug;25(5):929-41
pubmed: 16133944
Leuk Res. 2007 Jun;31(6):817-25
pubmed: 16876244
BMC Cancer. 2008 Oct 08;8:291
pubmed: 18840301
Am J Physiol Cell Physiol. 2012 May 1;302(9):C1271-81
pubmed: 22277755
Contemp Oncol (Pozn). 2014;18(5):307-12
pubmed: 25477751
Science. 1996 Jul 12;273(5272):245-8
pubmed: 8662509
J Cell Physiol. 2019 Feb;234(2):1398-1415
pubmed: 30078202
Science. 1997 Feb 28;275(5304):1308-11
pubmed: 9036856
J Cell Biol. 1990 Jan;110(1):165-74
pubmed: 1688561
Microsc Res Tech. 2009 Apr;72(4):310-6
pubmed: 19009596
Nat Cell Biol. 1999 Jul;1(3):136-43
pubmed: 10559899
Cell Stem Cell. 2017 Nov 2;21(5):591-603.e4
pubmed: 29100012
Sci Rep. 2020 Apr 3;10(1):5876
pubmed: 32246025
Neurochem Int. 2016 Jun;96:13-23
pubmed: 27094845
J R Soc Interface. 2017 Nov;14(136):
pubmed: 29118112
Cancers (Basel). 2019 May 09;11(5):
pubmed: 31075964
J Clin Transl Res. 2017 May 24;3(2):233-249
pubmed: 30873475
Neurochem Res. 2012 Sep;37(9):1967-81
pubmed: 22684283
Annu Rev Cell Dev Biol. 2010;26:315-33
pubmed: 19575647
J Cell Biol. 1987 Jun;104(6):1587-95
pubmed: 2438288
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100832
J Clin Oncol. 2017 Jul 20;35(21):2402-2409
pubmed: 28640706
Cancer Cell Int. 2005 May 10;5(1):13
pubmed: 15885136
Brain Res. 2007 May 29;1149:18-29
pubmed: 17408596
Oncotarget. 2016 Mar 22;7(12):14259-78
pubmed: 26893360
Science. 2003 Dec 5;302(5651):1704-9
pubmed: 14657486
Neuropathol Appl Neurobiol. 2003 Aug;29(4):370-7
pubmed: 12887597
Cell Mol Neurobiol. 2001 Aug;21(4):421-8
pubmed: 11775071
Circ Res. 2007 Mar 30;100(6):782-94
pubmed: 17395884
Neoplasia. 2008 Mar;10(3):198-206
pubmed: 18323016
J Cancer Res Clin Oncol. 2001 Apr;127(4):217-25
pubmed: 11315255
Anticancer Res. 2009 Jan;29(1):119-23
pubmed: 19331140
Cancer Res. 2003 Apr 1;63(7):1602-7
pubmed: 12670911
Nat Cell Biol. 2014 Feb;16(2):133-44
pubmed: 24463606
Genes Dis. 2016 May 11;3(3):198-210
pubmed: 30258889
J Biol Chem. 2012 Feb 3;287(6):4053-65
pubmed: 22130665
CNS Oncol. 2019 Jun;8(2):CNS37
pubmed: 31290679
PLoS One. 2014 Sep 11;9(9):e107292
pubmed: 25211468
Oncologist. 2019 Dec;24(12):e1426-e1436
pubmed: 31444292
Front Pharmacol. 2018 Sep 13;9:879
pubmed: 30271342
Mol Cell Neurosci. 2012 Mar;49(3):282-9
pubmed: 22197680
World J Biol Chem. 2017 Feb 26;8(1):4-12
pubmed: 28289514
Acta Pharmacol Sin. 2005 Mar;26(3):369-76
pubmed: 15715936
Br J Pharmacol. 2014 Dec;171(24):5507-23
pubmed: 24665826
Cancer Res. 2005 Oct 1;65(19):8792-800
pubmed: 16204049
J Neurosci. 2001 Oct 1;21(19):7674-83
pubmed: 11567057
Cancer Res. 2002 Sep 15;62(18):5336-43
pubmed: 12235004
Nat Rev Cancer. 2011 Jul 22;11(8):609-18
pubmed: 21779011